Decheng Capital LLC Lyell Immunopharma, Inc. Transaction History
Decheng Capital LLC
- $356 Billion
- Q1 2025
A detailed history of Decheng Capital LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Decheng Capital LLC holds 11,909,341 shares of LYEL stock, worth $107 Million. This represents 1.8% of its overall portfolio holdings.
Number of Shares
11,909,341
Previous 11,909,341
-0.0%
Holding current value
$107 Million
Previous $7.62 Billion
15.94%
% of portfolio
1.8%
Previous 1.63%
Shares
1 transactions
Others Institutions Holding LYEL
# of Institutions
117Shares Held
175MCall Options Held
2.9KPut Options Held
6K-
Mwg Management Ltd. Washington, DC20.2MShares$181 Million18.54% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA16MShares$144 Million9.84% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$136 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$136 Million9.84% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$121 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $2.23B
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...